Changes

{{Under Construction}}

{{Under Construction}}

<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-11-30. The original page can be found at [[HAEM4:Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable]].

<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-12-04. The original page can be found at [[HAEM4:Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable]].

}}</blockquote>

}}</blockquote>

==Primary Author(s)*==

==Primary Author(s)*==

When an underlying MPN has not been identified, the category of MDS/MPN-U is appropriate. <ref name=":0" />

When an underlying MPN has not been identified, the category of MDS/MPN-U is appropriate. <ref name=":0" />

Cases with features of MDS/MPN-U may arise due to prior exposure to treatment and are included in the [[Therapy-Related Myeloid Neoplasms|Therapy-related myeloid neoplasms]] (t-MN).

Cases with features of MDS/MPN-U may arise due to prior exposure to treatment and are included in the [[HAEM5:Myeloid neoplasm post cytotoxic therapy|Therapy-related myeloid neoplasms]] (t-MN).

Well-defined MPN which subsequently develop dysplastic features and progress to a more aggressive phase are excluded from this category.

Well-defined MPN which subsequently develop dysplastic features and progress to a more aggressive phase are excluded from this category.

<blockquote class='blockedit'>{{Box-round|title=v4:Clinical Features|The content below was from the old template. Please incorporate above.}}

<blockquote class='blockedit'>{{Box-round|title=v4:Clinical Features|The content below was from the old template. Please incorporate above.}}

*Overlap with [[Myelodysplastic Syndromes (MDS)|MDS]] and [[Myeloproliferative Neoplasms (MPN)|MPN]] <ref name=":0" />

*Overlap with [[HAEM4:Myelodysplastic Syndromes (MDS)|MDS]] and [[HAEM4:Myeloproliferative Neoplasms (MPN)|MPN]] <ref name=":0" />

*Clinically the most heterogeneous of the MDS/MPN <ref name=":3" />

*Clinically the most heterogeneous of the MDS/MPN <ref name=":3" />

*Does not have features that define it as belonging to any of the other categories of MDS/MPN <ref name=":0" /><ref name=":1" />

*Does not have features that define it as belonging to any of the other categories of MDS/MPN <ref name=":0" /><ref name=":1" />

<blockquote class='blockedit'>{{Box-round|title=v4:Immunophenotype|The content below was from the old template. Please incorporate above.}}

<blockquote class='blockedit'>{{Box-round|title=v4:Immunophenotype|The content below was from the old template. Please incorporate above.}}

May be similar to that of [[Myelodysplastic Syndromes (MDS)|MDS]] or [[Myeloproliferative Neoplasms (MPN)|MPN]] <ref name=":0" />

May be similar to that of [[HAEM4:Myelodysplastic Syndromes (MDS)|MDS]] or [[HAEM4:Myeloproliferative Neoplasms (MPN)|MPN]] <ref name=":0" />

</blockquote>

</blockquote>